The global Immuno-oncology Diagnosis market size was valued at US$ million in 2023. With growing demand in downstream market, the Immuno-oncology Diagnosis is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Immuno-oncology Diagnosis market. Immuno-oncology Diagnosis are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Immuno-oncology Diagnosis. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Immuno-oncology Diagnosis market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Immuno-oncology Diagnosis market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Immuno-oncology Diagnosis market. It may include historical data, market segmentation by Type (e.g., PCR, NGS), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Immuno-oncology Diagnosis market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Immuno-oncology Diagnosis market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Immuno-oncology Diagnosis industry. This include advancements in Immuno-oncology Diagnosis technology, Immuno-oncology Diagnosis new entrants, Immuno-oncology Diagnosis new investment, and other innovations that are shaping the future of Immuno-oncology Diagnosis.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Immuno-oncology Diagnosis market. It includes factors influencing customer ' purchasing decisions, preferences for Immuno-oncology Diagnosis product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Immuno-oncology Diagnosis market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Immuno-oncology Diagnosis market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Immuno-oncology Diagnosis market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Immuno-oncology Diagnosis industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Immuno-oncology Diagnosis market.
麻豆原创 Segmentation:
Immuno-oncology Diagnosis market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
PCR
NGS
Immunoassay
Segmentation by application
Research
Diagnostics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
10x Genomics
Abbott Laboratories
Abcam
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience
Angle plc
Apocell
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
BioCartis
Biocept
Biodesix Inc
BioFluidica
BioGenex 40 bioM茅rieux
Bio-Rad
Bio-Techne
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River Laboratories
Chronix Biomedical
Circulogene
Clearbridge BioMedics
Clinical Genomics
Pfizer
Promega
Protagen Diagnostics
Qiagen
Quanterix
Rarecells SAS
Roche Diagnostics
Siemens
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Immuno-oncology Diagnosis 麻豆原创 Size 2019-2030
2.1.2 Immuno-oncology Diagnosis 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Immuno-oncology Diagnosis Segment by Type
2.2.1 PCR
2.2.2 NGS
2.2.3 Immunoassay
2.3 Immuno-oncology Diagnosis 麻豆原创 Size by Type
2.3.1 Immuno-oncology Diagnosis 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Immuno-oncology Diagnosis 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Immuno-oncology Diagnosis Segment by Application
2.4.1 Research
2.4.2 Diagnostics
2.5 Immuno-oncology Diagnosis 麻豆原创 Size by Application
2.5.1 Immuno-oncology Diagnosis 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Immuno-oncology Diagnosis 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Immuno-oncology Diagnosis 麻豆原创 Size by Player
3.1 Immuno-oncology Diagnosis 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Immuno-oncology Diagnosis Revenue by Players (2019-2024)
3.1.2 Global Immuno-oncology Diagnosis Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Immuno-oncology Diagnosis Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Immuno-oncology Diagnosis by Regions
4.1 Immuno-oncology Diagnosis 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Immuno-oncology Diagnosis 麻豆原创 Size Growth (2019-2024)
4.3 APAC Immuno-oncology Diagnosis 麻豆原创 Size Growth (2019-2024)
4.4 Europe Immuno-oncology Diagnosis 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Immuno-oncology Diagnosis 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Immuno-oncology Diagnosis 麻豆原创 Size by Country (2019-2024)
5.2 Americas Immuno-oncology Diagnosis 麻豆原创 Size by Type (2019-2024)
5.3 Americas Immuno-oncology Diagnosis 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immuno-oncology Diagnosis 麻豆原创 Size by Region (2019-2024)
6.2 APAC Immuno-oncology Diagnosis 麻豆原创 Size by Type (2019-2024)
6.3 APAC Immuno-oncology Diagnosis 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Immuno-oncology Diagnosis by Country (2019-2024)
7.2 Europe Immuno-oncology Diagnosis 麻豆原创 Size by Type (2019-2024)
7.3 Europe Immuno-oncology Diagnosis 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Immuno-oncology Diagnosis by Region (2019-2024)
8.2 Middle East & Africa Immuno-oncology Diagnosis 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Immuno-oncology Diagnosis 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Immuno-oncology Diagnosis 麻豆原创 Forecast
10.1 Global Immuno-oncology Diagnosis Forecast by Regions (2025-2030)
10.1.1 Global Immuno-oncology Diagnosis Forecast by Regions (2025-2030)
10.1.2 Americas Immuno-oncology Diagnosis Forecast
10.1.3 APAC Immuno-oncology Diagnosis Forecast
10.1.4 Europe Immuno-oncology Diagnosis Forecast
10.1.5 Middle East & Africa Immuno-oncology Diagnosis Forecast
10.2 Americas Immuno-oncology Diagnosis Forecast by Country (2025-2030)
10.2.1 United States Immuno-oncology Diagnosis 麻豆原创 Forecast
10.2.2 Canada Immuno-oncology Diagnosis 麻豆原创 Forecast
10.2.3 Mexico Immuno-oncology Diagnosis 麻豆原创 Forecast
10.2.4 Brazil Immuno-oncology Diagnosis 麻豆原创 Forecast
10.3 APAC Immuno-oncology Diagnosis Forecast by Region (2025-2030)
10.3.1 China Immuno-oncology Diagnosis 麻豆原创 Forecast
10.3.2 Japan Immuno-oncology Diagnosis 麻豆原创 Forecast
10.3.3 Korea Immuno-oncology Diagnosis 麻豆原创 Forecast
10.3.4 Southeast Asia Immuno-oncology Diagnosis 麻豆原创 Forecast
10.3.5 India Immuno-oncology Diagnosis 麻豆原创 Forecast
10.3.6 Australia Immuno-oncology Diagnosis 麻豆原创 Forecast
10.4 Europe Immuno-oncology Diagnosis Forecast by Country (2025-2030)
10.4.1 Germany Immuno-oncology Diagnosis 麻豆原创 Forecast
10.4.2 France Immuno-oncology Diagnosis 麻豆原创 Forecast
10.4.3 UK Immuno-oncology Diagnosis 麻豆原创 Forecast
10.4.4 Italy Immuno-oncology Diagnosis 麻豆原创 Forecast
10.4.5 Russia Immuno-oncology Diagnosis 麻豆原创 Forecast
10.5 Middle East & Africa Immuno-oncology Diagnosis Forecast by Region (2025-2030)
10.5.1 Egypt Immuno-oncology Diagnosis 麻豆原创 Forecast
10.5.2 South Africa Immuno-oncology Diagnosis 麻豆原创 Forecast
10.5.3 Israel Immuno-oncology Diagnosis 麻豆原创 Forecast
10.5.4 Turkey Immuno-oncology Diagnosis 麻豆原创 Forecast
10.5.5 GCC Countries Immuno-oncology Diagnosis 麻豆原创 Forecast
10.6 Global Immuno-oncology Diagnosis Forecast by Type (2025-2030)
10.7 Global Immuno-oncology Diagnosis Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 10x Genomics
11.1.1 10x Genomics Company Information
11.1.2 10x Genomics Immuno-oncology Diagnosis Product Offered
11.1.3 10x Genomics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 10x Genomics Main Business Overview
11.1.5 10x Genomics Latest Developments
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Information
11.2.2 Abbott Laboratories Immuno-oncology Diagnosis Product Offered
11.2.3 Abbott Laboratories Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Abbott Laboratories Main Business Overview
11.2.5 Abbott Laboratories Latest Developments
11.3 Abcam
11.3.1 Abcam Company Information
11.3.2 Abcam Immuno-oncology Diagnosis Product Offered
11.3.3 Abcam Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Abcam Main Business Overview
11.3.5 Abcam Latest Developments
11.4 Adaptive Biotechnologies
11.4.1 Adaptive Biotechnologies Company Information
11.4.2 Adaptive Biotechnologies Immuno-oncology Diagnosis Product Offered
11.4.3 Adaptive Biotechnologies Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Adaptive Biotechnologies Main Business Overview
11.4.5 Adaptive Biotechnologies Latest Developments
11.5 Aethlon Medical
11.5.1 Aethlon Medical Company Information
11.5.2 Aethlon Medical Immuno-oncology Diagnosis Product Offered
11.5.3 Aethlon Medical Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Aethlon Medical Main Business Overview
11.5.5 Aethlon Medical Latest Developments
11.6 Agena Bioscience
11.6.1 Agena Bioscience Company Information
11.6.2 Agena Bioscience Immuno-oncology Diagnosis Product Offered
11.6.3 Agena Bioscience Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Agena Bioscience Main Business Overview
11.6.5 Agena Bioscience Latest Developments
11.7 Angle plc
11.7.1 Angle plc Company Information
11.7.2 Angle plc Immuno-oncology Diagnosis Product Offered
11.7.3 Angle plc Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Angle plc Main Business Overview
11.7.5 Angle plc Latest Developments
11.8 Apocell
11.8.1 Apocell Company Information
11.8.2 Apocell Immuno-oncology Diagnosis Product Offered
11.8.3 Apocell Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Apocell Main Business Overview
11.8.5 Apocell Latest Developments
11.9 ARUP Laboratories
11.9.1 ARUP Laboratories Company Information
11.9.2 ARUP Laboratories Immuno-oncology Diagnosis Product Offered
11.9.3 ARUP Laboratories Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 ARUP Laboratories Main Business Overview
11.9.5 ARUP Laboratories Latest Developments
11.10 Beckman Coulter
11.10.1 Beckman Coulter Company Information
11.10.2 Beckman Coulter Immuno-oncology Diagnosis Product Offered
11.10.3 Beckman Coulter Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Beckman Coulter Main Business Overview
11.10.5 Beckman Coulter Latest Developments
11.11 Becton Dickinson
11.11.1 Becton Dickinson Company Information
11.11.2 Becton Dickinson Immuno-oncology Diagnosis Product Offered
11.11.3 Becton Dickinson Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Becton Dickinson Main Business Overview
11.11.5 Becton Dickinson Latest Developments
11.12 Bioarray Genetics
11.12.1 Bioarray Genetics Company Information
11.12.2 Bioarray Genetics Immuno-oncology Diagnosis Product Offered
11.12.3 Bioarray Genetics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Bioarray Genetics Main Business Overview
11.12.5 Bioarray Genetics Latest Developments
11.13 BioCartis
11.13.1 BioCartis Company Information
11.13.2 BioCartis Immuno-oncology Diagnosis Product Offered
11.13.3 BioCartis Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 BioCartis Main Business Overview
11.13.5 BioCartis Latest Developments
11.14 Biocept
11.14.1 Biocept Company Information
11.14.2 Biocept Immuno-oncology Diagnosis Product Offered
11.14.3 Biocept Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Biocept Main Business Overview
11.14.5 Biocept Latest Developments
11.15 Biodesix Inc
11.15.1 Biodesix Inc Company Information
11.15.2 Biodesix Inc Immuno-oncology Diagnosis Product Offered
11.15.3 Biodesix Inc Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Biodesix Inc Main Business Overview
11.15.5 Biodesix Inc Latest Developments
11.16 BioFluidica
11.16.1 BioFluidica Company Information
11.16.2 BioFluidica Immuno-oncology Diagnosis Product Offered
11.16.3 BioFluidica Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 BioFluidica Main Business Overview
11.16.5 BioFluidica Latest Developments
11.17 BioGenex 40 bioM茅rieux
11.17.1 BioGenex 40 bioM茅rieux Company Information
11.17.2 BioGenex 40 bioM茅rieux Immuno-oncology Diagnosis Product Offered
11.17.3 BioGenex 40 bioM茅rieux Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 BioGenex 40 bioM茅rieux Main Business Overview
11.17.5 BioGenex 40 bioM茅rieux Latest Developments
11.18 Bio-Rad
11.18.1 Bio-Rad Company Information
11.18.2 Bio-Rad Immuno-oncology Diagnosis Product Offered
11.18.3 Bio-Rad Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Bio-Rad Main Business Overview
11.18.5 Bio-Rad Latest Developments
11.19 Bio-Techne
11.19.1 Bio-Techne Company Information
11.19.2 Bio-Techne Immuno-oncology Diagnosis Product Offered
11.19.3 Bio-Techne Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Bio-Techne Main Business Overview
11.19.5 Bio-Techne Latest Developments
11.20 Bristol-Myers Squibb
11.20.1 Bristol-Myers Squibb Company Information
11.20.2 Bristol-Myers Squibb Immuno-oncology Diagnosis Product Offered
11.20.3 Bristol-Myers Squibb Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Bristol-Myers Squibb Main Business Overview
11.20.5 Bristol-Myers Squibb Latest Developments
11.21 Cancer Genetics
11.21.1 Cancer Genetics Company Information
11.21.2 Cancer Genetics Immuno-oncology Diagnosis Product Offered
11.21.3 Cancer Genetics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.21.4 Cancer Genetics Main Business Overview
11.21.5 Cancer Genetics Latest Developments
11.22 Caris Molecular Diagnostics
11.22.1 Caris Molecular Diagnostics Company Information
11.22.2 Caris Molecular Diagnostics Immuno-oncology Diagnosis Product Offered
11.22.3 Caris Molecular Diagnostics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.22.4 Caris Molecular Diagnostics Main Business Overview
11.22.5 Caris Molecular Diagnostics Latest Developments
11.23 CellMax Life
11.23.1 CellMax Life Company Information
11.23.2 CellMax Life Immuno-oncology Diagnosis Product Offered
11.23.3 CellMax Life Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.23.4 CellMax Life Main Business Overview
11.23.5 CellMax Life Latest Developments
11.24 Charles River Laboratories
11.24.1 Charles River Laboratories Company Information
11.24.2 Charles River Laboratories Immuno-oncology Diagnosis Product Offered
11.24.3 Charles River Laboratories Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.24.4 Charles River Laboratories Main Business Overview
11.24.5 Charles River Laboratories Latest Developments
11.25 Chronix Biomedical
11.25.1 Chronix Biomedical Company Information
11.25.2 Chronix Biomedical Immuno-oncology Diagnosis Product Offered
11.25.3 Chronix Biomedical Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.25.4 Chronix Biomedical Main Business Overview
11.25.5 Chronix Biomedical Latest Developments
11.26 Circulogene
11.26.1 Circulogene Company Information
11.26.2 Circulogene Immuno-oncology Diagnosis Product Offered
11.26.3 Circulogene Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.26.4 Circulogene Main Business Overview
11.26.5 Circulogene Latest Developments
11.27 Clearbridge BioMedics
11.27.1 Clearbridge BioMedics Company Information
11.27.2 Clearbridge BioMedics Immuno-oncology Diagnosis Product Offered
11.27.3 Clearbridge BioMedics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.27.4 Clearbridge BioMedics Main Business Overview
11.27.5 Clearbridge BioMedics Latest Developments
11.28 Clinical Genomics
11.28.1 Clinical Genomics Company Information
11.28.2 Clinical Genomics Immuno-oncology Diagnosis Product Offered
11.28.3 Clinical Genomics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.28.4 Clinical Genomics Main Business Overview
11.28.5 Clinical Genomics Latest Developments
11.29 Pfizer
11.29.1 Pfizer Company Information
11.29.2 Pfizer Immuno-oncology Diagnosis Product Offered
11.29.3 Pfizer Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.29.4 Pfizer Main Business Overview
11.29.5 Pfizer Latest Developments
11.30 Promega
11.30.1 Promega Company Information
11.30.2 Promega Immuno-oncology Diagnosis Product Offered
11.30.3 Promega Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.30.4 Promega Main Business Overview
11.30.5 Promega Latest Developments
11.31 Protagen Diagnostics
11.31.1 Protagen Diagnostics Company Information
11.31.2 Protagen Diagnostics Immuno-oncology Diagnosis Product Offered
11.31.3 Protagen Diagnostics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.31.4 Protagen Diagnostics Main Business Overview
11.31.5 Protagen Diagnostics Latest Developments
11.32 Qiagen
11.32.1 Qiagen Company Information
11.32.2 Qiagen Immuno-oncology Diagnosis Product Offered
11.32.3 Qiagen Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.32.4 Qiagen Main Business Overview
11.32.5 Qiagen Latest Developments
11.33 Quanterix
11.33.1 Quanterix Company Information
11.33.2 Quanterix Immuno-oncology Diagnosis Product Offered
11.33.3 Quanterix Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.33.4 Quanterix Main Business Overview
11.33.5 Quanterix Latest Developments
11.34 Rarecells SAS
11.34.1 Rarecells SAS Company Information
11.34.2 Rarecells SAS Immuno-oncology Diagnosis Product Offered
11.34.3 Rarecells SAS Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.34.4 Rarecells SAS Main Business Overview
11.34.5 Rarecells SAS Latest Developments
11.35 Roche Diagnostics
11.35.1 Roche Diagnostics Company Information
11.35.2 Roche Diagnostics Immuno-oncology Diagnosis Product Offered
11.35.3 Roche Diagnostics Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.35.4 Roche Diagnostics Main Business Overview
11.35.5 Roche Diagnostics Latest Developments
11.36 Siemens
11.36.1 Siemens Company Information
11.36.2 Siemens Immuno-oncology Diagnosis Product Offered
11.36.3 Siemens Immuno-oncology Diagnosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.36.4 Siemens Main Business Overview
11.36.5 Siemens Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
